In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus▽

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1290-1292

  Calvo, Enrique ^a   Pastor, F Javier ^a   Mayayo, Emilio ^a   Salas, Valentina ^a   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; GALACTOMANNAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ECHINOCANDINS; MALE; MICE;

EID: 79952321919     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01282-10     Document Type: Article

References (19)

1. Arendrup, M. C., et al. 2008. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52:3504-3511.
2. Catalán, M., and J. C. Montejo. 2006. Systemic antifungals. Pharmacodynamics and pharmacokinetics. Rev. Iberoam. Micol. 23:39-49.
3. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of filamentous fungi; proposed guideline. Document M51-P. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Espinel-Ingroff, A., et al. 2007. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J. Clin. Microbiol. 45:1811-1820.
6. Hedayati, M. T., A. C. Pasqualotto, P. A. Warn, P. Bowyer, and D. W. Denning. 2007. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153:1677-1692.
7. Klont, R. R., et al. 2006. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin. Infect. Dis. 43:23-25.
8. Lewis, J. S., II. 2009. Echinocandin activity against Aspergillus spp. and the importance of pharmacodynamics. Med. Mycol. 47:376-381.
9. Morgan, J., et al. 2005. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43:49-58.
10. Nagasaki, Y., et al. 2009. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. J. Antimicrob. Chemother. 64:379-382.
11. Petraitis, V., et al. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
12. Roberts, J., K. Schock, S. Marino, and V. T. Andriole. 2000. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44:3381-3388.
13. Rodríguez, M. M., et al. 2009. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob. Agents Chemother. 53:5022-5025.
14. Sionov, E., S. Mendlovic, and E. Segal. 2006. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53:131-139. (Pubitemid 44028669)
15. van de Sande, W. W., et al. 2009. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother. 53:2005-2013.
16. Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.
17. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
18. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guideline of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
19. Wiederhold, N. P., et al. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 15:1464-1471.